MedTrace Logo

Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas

NCT06180434 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 320

Last updated 2024-10-15

No results posted yet for this study

Summary

Rationale:

Proton beam therapy has recently become available for the treatment of patients with WHO grade 2 and 3 IDH mutated (IDHmt) glioma in the Netherlands. The dose distributions associated with proton therapy have substantially reduced the volume of the normal brain irradiated with low and intermediate radiotherapy doses. Whether this impacts rates of progressive disease or safety issues and how this compares with a similar population treated with photon therapy is currently unknown.

Objective:

To investigate short term outcomes after proton and photon radiotherapy for grade 2 and 3 IDHmt glioma.

Conditions

  • Glioma
  • Radiotherapy; Complications

Interventions

RADIATION

proton therapy

Radiotherapy delivered with protons

RADIATION

photon therapy

Radiotherapy delivered with photons

Sponsors & Collaborators

  • Medical Center Haaglanden

    collaborator OTHER

  • Leiden University Medical Center

    collaborator OTHER

  • HollandPTC

    collaborator INDUSTRY

  • Institute Verbeeten

    collaborator OTHER

  • Universitaire Ziekenhuizen KU Leuven

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • Maastro Clinic, The Netherlands

    collaborator OTHER

  • Erasmus Medical Center

    lead OTHER

Principal Investigators

  • Alejandra Mendez Romero, MD PhD · Assitant Professor, Radiation Oncologist

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-02-01
Completion
2025-11-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06180434 on ClinicalTrials.gov